Pipeline news
-
Slone Partners Recruits Chief Medical Officer for Epic Sciences
21 May 2019
Executive search firm Slone Partners has placed Richard Wenstrup as the chief medical officer of Epic Sciences. “Dr. Wenstrup’s decades-long experience in oncology leadership and clinical work will add substantial value to Epic Sciences in developing exciting new diagnostic tests that advance the mission of precision medicine,” said Tara Kochis-Stach, president of Slone Partners.
-
17 May 2019
Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced that data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), will be the subject of a poster presentation at the 2019 ASCO Annual Meeting being held in Chicago May 31 to June 4, 2019.
-
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
15 May 2019
Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update.
-
binx health Receives CE Mark for Rapid Chlamydia and Gonorrhea Test for Mass Markets
15 May 2019
binx health, the pioneer in anywhere care today announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval. The new multiplex test works with the binx io platform, delivering a laboratory-quality result in about 30 minutes, creating a new model for “test-and-treat” care for two of the most prevalent Sexually Transmitted Infections (STIs) globally.
-
06 May 2019
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2019 . In addition, the Company provided a clinical and business update. As of March 31, 2019 , Syndax had $92.7 million in cash, cash equivalents and short-term investments.
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
01 May 2019
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2019.
-
01 May 2019
Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations were made on Clearside’s Suprachoroidal Space (SCS) injection platform at ophthalmology and gene therapy medical meetings in Vancouver, British Columbia . The presentations highlighted the potential benefits of Clearside’s SCS injection platform when utilized in uveitis patients and with gene therapy.
-
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
22 April 2019
Epic Sciences, Inc. announced today the appointment of Richard J. Wenstrup, M.D. as chief medical officer. In this role, Dr. Wenstrup will lead clinical development, regulatory and medical affairs strategies for the company and be responsible for advancing the company’s clinical research and product development pipeline.
-
Slone Partners, Where People Are Our Science®, Places Lloyd Sanders As CEO At Epic Sciences, Inc
18 April 2019
Slone Partners, North America’s leading executive search firm for life sciences and diagnostics companies, announces the placement of Lloyd Sanders at Epic Sciences, Inc. as Chief Executive Officer. With headquarters in San Diego, California, Mr. Sanders is responsible for all strategic and business aspects of the oncological diagnostics company.
-
Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO
08 April 2019
Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Board of Directors has appointed seasoned biopharmaceutical executive George Lasezkay, Pharm.D., J.D. to the position of Interim Chief Executive Officer, effective immediately.
